Data / Drug companies / AvKARE
AvKARE: 79 products in the FDA NDC directory, labeler code 73190
AvKARE (labeler code 73190) lists 79 products in the FDA National Drug Code Directory, covering 35 finished drugs by generic name. By type: 79 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 30, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73190
- Products in commercial distribution
- 79
- Packages
- 97
- Finished drugs by generic name
- 35
- Prescription products
- 79
- Over the counter products
- 0
- Controlled substance products
- Schedule II 3, Schedule V 5
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 55
- Earliest marketing start
- January 21, 2025
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 76 | 96.2% |
| New drug applications (NDA) | 3 | 3.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 79 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 35 | 44.3% |
| Tablet | 19 | 24.1% |
| Capsule | 14 | 17.7% |
| Capsule, extended release | 6 | 7.6% |
| Tablet, film coated, extended release | 3 | 3.8% |
| Solution | 1 | 1.3% |
| Suspension | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mirabegron | 73190-116 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 30, 2026 |
| Mirabegron | 73190-115 | Tablet, film coated, extended release | Generic drugs (ANDA) | October 30, 2026 |
| Amlodipine Besylate and Benazepril Hydrochloride | 73190-024 | Capsule | Generic drugs (ANDA) | October 29, 2026 |
| Amlodipine Besylate and Benazepril Hydrochloride | 73190-022 | Capsule | Generic drugs (ANDA) | October 29, 2026 |
| Amlodipine Besylate and Benazepril Hydrochloride | 73190-021 | Capsule | Generic drugs (ANDA) | October 29, 2026 |
| Amlodipine Besylate and Benazepril Hydrochloride | 73190-020 | Capsule | Generic drugs (ANDA) | October 29, 2026 |
| Tapentadol Hydrochloride | 73190-083 | Tablet, film coated | Generic drugs (ANDA) | September 14, 2026 |
| Tapentadol Hydrochloride | 73190-082 | Tablet, film coated | Generic drugs (ANDA) | September 14, 2026 |
| Tapentadol Hydrochloride | 73190-081 | Tablet, film coated | Generic drugs (ANDA) | September 14, 2026 |
| Lacosamide Oral Solution | 73190-103 | Solution | Generic drugs (ANDA) | September 9, 2026 |
| Deferiprone | 73190-095 | Tablet | Generic drugs (ANDA) | August 12, 2026 |
| Tofacitinib | 73190-101 | Tablet, film coated | Generic drugs (ANDA) | July 23, 2026 |
| Tofacitinib | 73190-100 | Tablet, film coated | Generic drugs (ANDA) | July 23, 2026 |
| Nintedanib | 73190-097 | Capsule | Generic drugs (ANDA) | July 21, 2026 |
| Nintedanib | 73190-096 | Capsule | Generic drugs (ANDA) | July 21, 2026 |
| Famciclovir | 73190-093 | Tablet, film coated | Generic drugs (ANDA) | July 21, 2026 |
| Famciclovir | 73190-092 | Tablet, film coated | Generic drugs (ANDA) | July 21, 2026 |
| Famciclovir | 73190-091 | Tablet, film coated | Generic drugs (ANDA) | July 21, 2026 |
| Olmesartan medoxomil-hydrochlorothiazide | 73190-080 | Tablet, film coated | New drug applications (NDA) | July 14, 2026 |
| Olmesartan medoxomil-hydrochlorothiazide | 73190-079 | Tablet, film coated | New drug applications (NDA) | July 14, 2026 |
| Olmesartan medoxomil-hydrochlorothiazide | 73190-078 | Tablet, film coated | New drug applications (NDA) | July 14, 2026 |
| Tofacitinib | 73190-102 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 24, 2026 |
| Roflumilast | 73190-087 | Tablet | Generic drugs (ANDA) | June 24, 2026 |
| Roflumilast | 73190-086 | Tablet | Generic drugs (ANDA) | June 24, 2026 |
| Amantadine hydrochloride | 73190-094 | Capsule | Generic drugs (ANDA) | June 17, 2026 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.